Circio Holding ASA: Registration of share capital increase following conversion of convertible bonds

04 Jul 2025 09:22 CEST

Oslo, 4 July 2025: Reference is made to the stock exchange announcement by
Circio Holding ASA (OSE:CRNA) (the "Company") on 30 June 2025, regarding the
requested conversion of convertible bonds by Atlas Special Opportunities, LLC.

The share capital increase has now been registered with the Norwegian Register
of Business Enterprises (Nw. Foretaksregisteret). The Company's new share
capital is NOK 63,305,046.60 divided into 105,508,411 shares, each with a
nominal value of NOK 0.60.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com

Lubor Gaal, CFO
Phone: +34 683 34 3811
Email: lubor.gaal@circio.com

About Circio
Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing powerful circular RNA
vector expression technology for next generation nucleic acid medicine.

Circio has established a unique circular RNA (circRNA) vector expression
technology for next generation RNA, DNA and viral therapeutics. The
proprietary circVec platform is based on a modular genetic cassette design for
efficient biogenesis of multifunctional circRNA inside cells. The circVec
platform has applications in multiple therapeutic settings, including genetic
medicine, cell therapy and chronic disease. It has demonstrated over 70-fold
prolonged RNA half-life and up to 15-fold enhanced protein expression vs.
conventional mRNA vector systems in vivo, and has the potential to become a
new gold-standard protein expression technology. The circRNA R&D activities
are being conducted by the wholly owned subsidiary Circio AB in Stockholm,
Sweden.

In parallel, Circio is continuing to develop its legacy immuno-oncology
program, TG01, through cost-efficient external academic and industry
collaborations. TG01 targets RAS-mutated cancers and is being tested in two
clinical trials in Norway and the USA. TG01 is a therapeutic peptide vaccine
adjuvanted by STIMULON QS-21 licensed from Agenus Inc.

More information:
Access the news on Oslo Bors NewsWeb site